TABLE 2.
The treatment of IgA nephropathy patients with isolated hematuria who underwent repeat biopsies (n = 29).
| Patient | Treatment | Patient | Treatment |
|---|---|---|---|
| 1 | RASB + PDN + TwHF + AZA | 16 | RASB |
| 2 | RASB + PDN + AZA | 17 | RASB + PDN + MMF |
| 3 | RASB | 18 | PDN + TwHF + AZA |
| 4 | RASB + PDN + TwHF | 19 | PDF + MMF |
| 5 | RASB | 20 | RASB |
| 6 | RASB + PDN + TwHF + AZA | 21 | PDF + MMF |
| 7 | PDN | 22 | PDF + MMF |
| 8 | PDN + TwHF + AZA | 23 | PDF + CTX |
| 9 | RASB + PDN + TwHF + AZA | 24 | PDF + MMF |
| 10 | PDF + MMF | 25 | PDN + AZA |
| 11 | RASB + PDN + AZA | 26 | RASB + PDN + MMF |
| 12 | RASB + PDN + MMF | 27 | PDF + CTX |
| 13 | RASB + PDN + AZA | 28 | PDF + MMF |
| 14 | TwHF | 29 | RASB + PDN + CTX |
| 15 | RASB + PDN + TwHF |
Note: RASB, renin-angiotensin system blockade; PDN, prednisone; TwHF, Tripterygium wilfordii Hook F; AZA, azathioprine; CTX, cyclophosphamideand MMF, mycophenolate mofetil.